Barclays
CAPR icon

Barclays’s Capricor Therapeutics CAPR Stock Holding History

Barclays’s Portfolio CAPR Stock Details CAPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.62M Sell
67,440
-247,352
-79% -$7.5M ﹤0.01% 2469
2026
Q1 		$9.57M Buy
314,792
+195,420
+164% +$5.21M ﹤0.01% 1470
2025
Q4 		$3.45M Buy
119,372
+64,279
+117% +$839K ﹤0.01% 2513
2025
Q3 		$397K Sell
55,093
-75,818
-58% -$558K ﹤0.01% 3946
2025
Q2 		$1.3M Buy
130,911
+53,362
+69% +$564K ﹤0.01% 3158
2025
Q1 		$736K Sell
77,549
-12,101
-13% -$168K ﹤0.01% 3287
2024
Q4 		$1.24M Buy
89,650
+53,354
+147% +$935K ﹤0.01% 3231
2024
Q3 		$552K Buy
36,296
+18,724
+107% +$92.6K ﹤0.01% 3714
2024
Q2 		$83.8K Buy
+17,572
New +$98K ﹤0.01% 3991
2021
Q4 		– Sell
-6,330
Closed -$25K – 4168
2021
Q3 		$25K Buy
6,330
+4,501
+246% +$20.5K ﹤0.01% 4329
2021
Q2 		$9K Buy
1,829
+1,731
+1,766% +$7.33K ﹤0.01% 4670
2021
Q1 		$0 Buy
+98
New +$564 ﹤0.01% 4727

Other funds holding CAPR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BCM
Boxer Capital Management San Diego, California $1.33B AUM 864.5% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Barclays's CAPR Position: Q2 2026 in Review

Barclays reduced its Capricor Therapeutics (CAPR) stake by 79% in Q2 2026, selling an estimated $7.5M and leaving 67,440 shares worth $1.62M. The position accounts for ﹤0.01% of the portfolio, ranked #2469.

Barclays first reported a position in CAPR in Q1 2021 and has held it in 12 quarters since. The position peaked at $9.57M in Q1 2026. 170 funds tracked by Wall St. Rank hold CAPR as of Q2 2026.

  • Barclays held 67,440 shares of Capricor Therapeutics worth $1.62M as of Q2 2026.
  • Barclays sold 247,352 Capricor Therapeutics shares in Q2 2026, an estimated $7.5M.
  • Capricor Therapeutics made up ﹤0.01% of Barclays's portfolio in Q2 2026, its #2469 holding.
  • Barclays first reported a position in Capricor Therapeutics in Q1 2021 and has held it in 12 quarters since.
  • Barclays's Capricor Therapeutics position peaked at $9.57M in Q1 2026.
  • 170 funds tracked by Wall St. Rank held Capricor Therapeutics as of Q2 2026.

Based on Barclays's 13F filing for Q2 2026, filed 14 Aug 2026.